SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although Nies et al. concluded that OCT-1 did not transport imatinib into primitive leukemic cells and corroborated previous studies demonstrating that OCT-1 activity varied in primary CML cells, the study did not investigate its relevance as a biomarker.